MYOCARDIAL OXYGEN DEMANDS are met by variations of coronary blood flow, which may be mediated by endogenous chemical substances, such as adenosine, prostaglandins and catecholamines. Among these, prostaglandin-like substances (prostanoids) have recently been considered in the ischemic myocardium to serve as potent determinants of coronary vascular tone and regional blood flow.'~" Such vasoactive prostanoids were identified as thromboxane A2 and prostaglandin 12, which possess opposite effects on the control of vascular tone. Thus, thromboxane A2, which is produced by an enzyme of platelet microsomes,' causes vasoconstriction' and increases platelet aggregability;7 prostaglandin 12, which is produced by an enzyme of vascular microsomes,8 causes vasodilation' 9 and decreases platelet aggregability. 10' 1 Thromboxane A2 and prostaglandin 12 are extremely labile substances, with half-lives of 30 seconds and 10 minutes, respectively. Thus, they are readily converted to thromboxane B2 and 6-keto- prostaglandin (PG) F1 ,, respectively, biologically inactive and chemically stable catabolites, which are assayable through radioimmunoassay12 18 or gas chromatography-mass spectrometry.14 Coronary vasospasm, or abnormally increased coronary vascular tone, has recently been postulated to initiate the pathologic events associated with angina pectorisl6' 18 and acute myocardial infarction;'7' 18 however, acute coronary thrombosis is also considered a pathogenic trigger'9' 20 in these diseases. In variant angina, the occurrence of coronary vasospasm is widely recognized. 21 24 Experimental evidence suggests that the contraction of coronary vessels and aggregability of blood platelets are interrelated and can be mediated by vasoactive prostanoids such as thromboxane A2 and prostaglandin 12 in the coronary circulation under normal or ischemic conditions.25-27 Therefore, it is clinically important to determine whether these prostanoids are associated with pathologic events, such as coronary vasospasm and thromboembolism, in patients with coronary artery disease. In cases with effort angina, platelet counts in the coronary sinus are significantly lower than those in the root of the aorta,28 possibly resulting from altered biosynthesis of vasoactive prostanoids within atherosclerotic vasculature that could increase platelet destruction. In our preliminary work determining plasma levels of radioimmunoassayable thromboxane B2, a circulating catabolite of thromboxane A2, we found that most patients with effort angina have increased thromboxane B2 levels in peripheral venous blood and coronary sinus blood, both at rest and during atrial pacing stress.2' &' Lewy et al. 3' reported that patients with unstable angina have increased thromboxane B2 in the coronary sinus during pacing-induced ischemia. Even greater increases in peripheral levels of thromboxane B2 have been found in patients with variant angina.29 32 The present study was undertaken to further delineate the role of altered thromboxane metabolism in patients with classic effort angina and in patients with variant angina. Thromboxane B2 levels were measured in the peripheral and coronary circulation under resting conditions and during angina that occurred spontaneously or was induced by atrial pacing or ergonovine.
Materials and Methods Patient Population
Thirty patients with angina pectoris (23 males and seven females; mean age 56 years, range 41-68 years) were studied. Eighteen patients had effort angina and 12 had variant angina. The patients with effort angina had typical angina on exertion documented by supine bicycle ergometer with evidence of ischemic ST-segment depression, and had angiographically documented stenosis (more than 75%) in one, two or all of the major coronary arteries. Those with variant angina had spontaneous angina with ST-segment elevation (more than 0.2 mV), and seven of these patients had no Ergonovine maleate was administered intravenously in the superior vena cava through a SwanGanz catheter as 0.1-mg bolus injections every 3-4 minutes until induction of typical angina or a maximal total dose of 0.4 mg. When angina was induced, a coronary angiogram was taken immediately after blood sampling and measurement of coronary sinus blood flow. Immediately after withdrawal into the syringe, 5-ml aliquots were transferred into polypropyrene tubes containing 1-mM ethylenediamine tetraacetic acid (EDTA) and 0.1 mM indomethacin (in final concentration) for assays of thromboxane B2. Other aliquots were transferred to determine lactate, oxygen and carbon dioxide. Samples were stored on ice until completion of the stress tests. After the test, plasma was separated by centrifugation at 1500 g for 20 minutes.
Radioimmunoassay for Thromboxane B2 Anti-thromboxane B2 antisera were supplied by the Upjohn Company, Kalamazoo, Michigan. The [5,6, minutes) and dehydrated by anhydrous Na2SO. Onemilliliter plasma extracts were evaporated to dryness under nitrogen at 40-55°C and resuspended in 0.1 M phosphate-buffered saline (0.9%), pH 7.4, with gelatin (0.1%), diluted appropriately (usually 1:4), and subjected to incubation with antisera and tritiated compounds. Then, 0.05 ml of [3H]thromboxane B2 (15,000 cpm) was added to antiserum (0.05 ml), which was appropriately diluted (usually 1:400 to 1:1000). The final assay volume was 0.15 ml. The mixtures were incubated for 60 minutes at room temperature and left standing at 4°C for 16-24 hours. Antibody-bound thromboxane B2 was separated from unbound compound with 0.1 ml of dextran-coated charcoal (mixture of 0.375 mg of dextran and 3.75 mg of charcoal) by centrifugation at 12,000 g for 30 seconds and supernatant containing antibody-bound thromboxane B2 was counted. All assays had 95% recovery efficiency. The sensitivity of the assay was 10 pg per plasma sample (0.25 ml), and a slight cross-reactivity was seen only with prostaglandin D2 with which relative crossreaction was less than 1%. The ability of the assay to detect known amounts of thromboxane B2 is shown in figure 1 . Plasma thromboxane B2 determinations were expressed in pg/ml of plasma. In our laboratory, this method has a coefficient of variation of 10% for duplicate determination. Net Ten patients with effort angina were subjected to atrial pacing. In all cases, percent lactate extraction at rest (33 ± 14%) markedly reduced at peak pacing (4 ± 20%), which was accompanied, in eight cases, by typical angina. Another four cases with a chest pain syndrome who had normal coronary arteriograms and did not develop angina or produce lactate during pacing served as control subjects. Representative findings in a patient with effort angina are shown in figure 3 . The thromboxane B2 levels in the coronary sinus and in the aorta at rest were significantly higher than in normal subjects. Coronary sinus blood flow increased gradually from the control value of 53 ml/min to 96 mi/min at peak pacing and then decreased to the basal level after pacing. Thromboxane B2 production in coronary circulation was estimated by multiplying the arterial-coronary sinus difference in thromboxane B2 levels by coronary sinus blood flow. Production was 37.3 ng/min at peak pacing in the case shown in figure  3 , in contrast to the four controls, who did not show thromboxane B2 production during pacing. For the group of patients with effort angina, arterial thromboxane B2 levels were either constant or slightly decreased during atrial pacing, whereas thromboxane B2 levels in coronary sinus showed moderate to marked increases with increased coronary sinus blood flow. In 10 patients with effort angina, thromboxane B2 production in coronary circulation at rest (-2.3 ± 14.8 ng/min) rose markedly during pacing-induced ischemia (34.7 ± 50.6 ng/min; p < 0.01), while in four controls the value at rest (-1.0 i: 4.0 ng/min) did not change significantly at peak pacing (-1.5 ± 10.9 ng/min) ( fig. 4) . Six of the 10 patients with effort angina had markedly increased thromboxane B2 production in the coronary circulation during peak pacing.
Thromboxane B2 Alterations During Ischemia in Patients with Variant Angina
Atrial pacing was performed in four patients with variant angina who had exertional angina as well as rest angina accompanied by typical ST-segment elevation. In none of these cases were significant stenotic lesions demonstrable during coronary angiography performed after blood sampling. The changes in by a rapid distribution phase, which may be followed by a more stable phase. Blood platelets are labile corpuscles that can readily aggregate and produce an artifactual increase in thromboxane levels during and after blood sampling. Therefore, in the present study, samples were mixed with EDTA and indomethacin in polypropylene tubes immediately after withdrawal. This technique halted platelet aggregation and inhibited the enzynme cyclo- FIGURE 5. Elevation of thromboxane B2 levels in patients with variant angina induced by atrial pacing. In case 1, angina was induced at a pacing rate of 110 beats/min, which was incompletely relieved by nitroglycerin (NTG) administered at 13.5 minutes. In case 2, angina was induced at the pacing rate of 1SO beats/min, which was immediately relieved by cessation ofpacing. The pacing rates are indicated at the bottom of the figure. Ao = aorta; Cs = coronary sinus; CsBF = coronary sinus blood flow. oxygenase. We29 and others28 have demonstrated that plasma thromboxane B2 levels and platelet aggregability are not affected by these sampling procedures. Silver et al. 38 showed that ex vivo prostaglandin formation by human platelets could not be demonstrated when platelets were removed by centrifuging blood in the presence of EDTA. Therefore, values probably represent true levels of plasma thromboxane B2 rather than artifacts that might be introduced during and after blood sampling.
Plasma levels of thromboxane B2 were determined in the peripheral and coronary circulation in patients with angina pectoris to define the possible involvement of this prostanoid in the pathologic events associated with angina. In patients with severe coronary artery stenosis and effort angina, thromboxane B2 in a peripheral vein and in the coronary sinus were significantly increased at rest. During myocardial ischemia produced by atrial pacing, a significant increase in thromboxane B2 production coincided with the onset of angina in more than 50% of cases. The observed thromboxane production during pacing-induced myocardial ischemia is essentially in accord with the report by Lewy et al.,3" who showed by using slightly different assay procedures that atrial pacing stress resulted in significant release of thromboxane B2 in almost 60% of cases with severe coronary stenosis (unstable angina). However, their thromboxane assay was not sensitive enough to detect thromboxane B2 levels below 200 pg/ml (0.5 pmol/ml), probably because they used antisera with sensitivity relatively lower than ours, and they incubated the antisera with patient plasma without extracting thromboxane B2. The sensitivity of our assay method exceeds that of Lewy et al.,3" in that as little as 40 pg/ml (0.1 pmol/ml) of thromboxane B2 could be detected, enabling us to define normal range of peripheral thromboxane B2 levels (254 ± 89 pg/ml, or 0.69 + 0.24 pmol/ml) and to detect subtle increments in peripheral and coronary sinus levels of thromboxane B2 in angina pectoris.
The present report indicates that many, but not all, patients with effort angina have significant increases in peripheral thromboxane B2 levels during nonanginal periods. Atrial pacing-induced augmentation of thromboxane B2 in the coronary sinus reported by Lewy et al.3' (260-4800 pg/ml, or 0.7-13 pmol/ml) was well above their assay threshold, and was on the same order of magnitude as that in the present report (300-1300 pg/ml). Also, in the present study, coronary sinus blood flow was measured during atrial pacing, which substantiated the increased production of thromboxane B2 in coronary circulation. Thus, using more sensitive assay procedures, we defined normal levels of thromboxane B2 and could examine more quantitatively the increased production of thromboxane B2 in coronary circulation during pacinginduced ischemia.
All patients with variant angina showed markedly increased thromboxane B, levels in peripheral blood during nonanginal periods. In some cases with variant angina, pacing stress induced a marked increase in thromboxane B2 in the coronary sinus and in the aortic root. This increase occurred before or with the onset of angina. An increase in thromboxane B, in the coronary sinus was also found during spontaneously or ergonovine-induced vasospastic attacks. These results suggest that an increased production of thromboxane A2 is associated with angina in patients with variant angina. From the present study, we do not know WA Control. 1113 whether increases in plasma thromboxane B2 are of primary or secondary significance. Excessive thromboxane release could cause vasospasm and/or increased platelet aggregability. Alternatively, coronary vasospasm could be the primary event: The spasminduced regional ischemia might lead to an increase in thromboxane formation derived from circulating blood platelets. The observed thromboxane increases in the coronary sinus during coronary spasm is in accord with the report by Robertson et al.," who showed that coronary sinus blood in patients with variant angina may contain increased numbers of platelet aggregates during vasospastic attack. During spasm and myocardial ischemia, levels of thromboxane B2 in both aortic and coronary sinus are augmented in almost all cases. These observations led us to speculate that a significant amount of thromboxane A2 in patients with variant angina may be derived from a tissue such as pulmonary tissue that is proximal to the heart. These findings explain why Raynaud's phenomenon is associated with variant angina.40 It would be interesting to examine whether thromboxane B2 flux from the pulmonary tissue is increased, particularly under conditions where hyperventilation" is the predominant cause in inducing coronary vasospasm. The present indication that increased peripheral thromboxane B2 levels are associated with variant angina may be clinically significant in that vasospastic disorders are related to the altered metabolism of thromboxanes. It is not known if the observed elevation of thromboxane B2 is primarily derived from the altered platelet function or is caused secondarily by the altered metabolism of prostaglandin 12 in the vascular wall.
Mehta et al.26 found that platelet counts in the coronary sinus in patients with severe coronary stenosis are markedly decreased. Thus, the production of thromboxane B2 in patients with effort angina may be associated with increased destruction of blood platelets as they circulate through impaired coronary vessels. This contention may be supported by the present findings that in patients with effort angina, the pacing stress induced marked increases in net release of thromboxane B2 from the coronary circulation ( figs. 3 and  4) . However, the increase could also be produced by increased arachidonic acid release into the coronary circulation during ischemia;42 increased arachidonic acid levels may produce an increase in thromboxane A2 by serving as a substrate for tissue cyclooxygenase, resulting in increased prostaglandin H2, a precursor of thromboxane A2.
That some patients with effort angina do not have increased thromboxane B2 levels in peripheral blood ( fig. 2 ) and thromboxane B2 release in coronary circulation ( fig. 4) indicates that in some cases, increased thromboxane A2 production is not required for the pathogenesis of angina. In such patients, exertional angina may be produced by relative ischemia caused by stenotic arteries rather than coronary vasospasm. Thromboxane B2 production may also reflect the state of impairment of the vascular wall; a metabolically active vascular lesion may induce platelet aggregability, Thus, the finding that plasma thromboxane B2 levels increase in peripheral and coronary circulation of many patients with effort angina and variant angina might be closely related to the pathologic events, such as coronary vasospasm and thromboembolism. It is of clinical interest to examine whether platelet-suppressant drugs may antagonize such pathologic events found in coronary artery disease. Frishman et al. '3 documented that propranolol abolishes platelet hyperresponsiveness to ADP in patients with angina pectoris, but it is not well known whether propranolol could reduce thromboxane metabolism or modulate another important mechanism that governs functions of platelets or other cardiovascular tissues. It is also undefined whether thromboxane metabolism in platelets could be altered by the platelet suppressants, which are functionally varied, such as f,-blocking agents, cyclooxygenase inhibitors and phosphodiesterase inhibitors. Therefore, the therapeutic significance of the present study must be examined in terms of the role of platelet-suppressant therapy.
Further work may demonstrate that determination of plasma thromboxane B2 levels may be of clinical diagnostic value, permitting assessment of severity of disease by the evaluation of the extent to which vascular wall and platelet functions are impaired. It is also important to define plasma levels of 6-keto-PGF,a, a catabolite of prostaglandin 12 that is supposed to counteract thromboxane A2, in patients with impaired coronary arteries.
